Claudia Fox, ENDO 2021: Exenatide for Weight Loss Maintenance in Adolescents
We were delighted to talk to Professor Claudia Fox (University of Minnesota, Minneapolis, MN, US) around the use of exenatide for weight loss maintenance among adolescents with severe obesity.
‘Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial.‘ (PRESENTATION NUMBER: OR02-4) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.
- What are the major challenges to weight loss maintenance among adolescents with severe obesity? (0:25)
- What is the rationale for the use of exenatide in non-diabetic obese adolescents? (2:26)
- Could you tell us a little about the aims, design and inclusion criteria of your study? (4:08)
- What were the efficacy and safety findings of the study? (5:39)
- What are the implications of these findings for the routine use of exenatide for weight loss maintenance among adolescents with severe obesity, and what questions remain unanswered? (7:52)
Disclosures: Claudia Fox discloses receiving research support from Novo Nordisk and Rhythm Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ENDO 2021 (Virtual).
Share this Video
Related Videos In Obesity
Domenica Rubino, EASD 2022: The role of semaglutide in the treatment paradigm for prediabetes
Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes. The abstract entitled: ‘Semaglutide 2.4 mg […]
Domenica Rubino, EASD 2022: Semaglutide 2.4 mg vs liraglutide 3.0 mg on glucose metabolism – STEP 8 post-hoc analysis
The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the […]
Uberto Pagotto, ESPE 2022: GLP-1 agonists and other emerging treatments of obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!